par Ramos, Ana Raquel 
;Bregni, Giacomo ;Gillet, Nadia ;Ando, Kunie ;Bodart, Cyril ;Vercauteren Drubbel, Alizée ;Descampe, Louison ;Moresi, Fabiana ;Bisteau, Xavier ;Verheye, Quentin ;Pirard, Sheleya ;Erneux, Christophe ;Beck, Benjamin
Référence Molecular cancer, 24, 1, page (280)
Publication Publié, 2025-11-01
;Bregni, Giacomo ;Gillet, Nadia ;Ando, Kunie ;Bodart, Cyril ;Vercauteren Drubbel, Alizée ;Descampe, Louison ;Moresi, Fabiana ;Bisteau, Xavier ;Verheye, Quentin ;Pirard, Sheleya ;Erneux, Christophe ;Beck, Benjamin Référence Molecular cancer, 24, 1, page (280)
Publication Publié, 2025-11-01
Article révisé par les pairs
| Résumé : | Drug synergy in cancer therapy has gained attention for its potential to enhance efficacy and minimize adverse effects. Synergy, where the combined effect of drugs exceeds the sum of their individual effects, is beneficial in addressing tumor heterogeneity and drug resistance in oncology. Esophageal squamous cell carcinoma (eSCC), accounting for over 85% of esophageal cancer cases, has a poor prognosis and limited therapeutic options. Targeted therapies have shown inefficiency in eSCC due to resistance mechanisms, making drug combination an interesting option. |
